Head-to-head evidence
AADvac1 vs NIO752
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline
AADvac1
Developed by Axon Neuroscience
NCT02579252 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 208 participants, with safety as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: August 2028 · NCT07167966 (registry estimate)
NIO752
Developed by Novartis
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AADvac1's landscape · NIO752's landscape